An expenditure analysis of high-cost medicaid recipients with hiv disease in New York State

Journal of Health Care for the Poor and Underserved

Volumn 22, Issue 1, 2011, Pages 330-345

  Chesnut, Thomas J ^a   Laufer, Franklin N ^b   Carrascal, Alvaro F ^c   Feldman, Ira S ^b  

^a AIDS Institute (NYSDOHAI)   (United States)

^b HIV Medicaid Policy and Programs   (United States)

^c HIV Health Care   (United States)

Author keywords

Expenditures; Medicaid; New York State; People living with HIV disease

Indexed keywords

ADDICTION; ADOLESCENT; ADULT; ARTICLE; CHILD; CHRONIC DISEASE; COMORBIDITY; ECONOMICS; FEMALE; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MALE; MEDICAID; MENTAL DISEASE; MIDDLE AGED; PRESCHOOL CHILD; PREVALENCE; RETROSPECTIVE STUDY; STATISTICS; UNITED STATES;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; COMORBIDITY; FEMALE; HEALTH EXPENDITURES; HIV INFECTIONS; HUMANS; INFANT; MALE; MEDICAID; MENTAL DISORDERS; MIDDLE AGED; NEW YORK; PREVALENCE; RETROSPECTIVE STUDIES; SUBSTANCE-RELATED DISORDERS; UNITED STATES; YOUNG ADULT;

EID: 79951616758     PISSN: 10492089     EISSN: 15486869     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. New York State Division of the Budget. 2009-2010 Executive Budget-Briefing Book. http://www.budget.state.ny.us/pubs/archive/fy0910archive/ eBudget0910/fy0910little book/BriefingBook.pdf. Accessed 2008 Dec 24.
2. Aracena B, Gutierrez J, Bertozzi SM, et al. Cost of AIDS care in Mexico: What are its main individual predictors? Arch Med Res. 2005 Sep-Oct;36(5):560-6. (Pubitemid 41140066)
3. Hutchinson AB, Farnham PG, Dean HD, et al. The economic burden of HIV in the United States in the era of highly active antiretroviral therapy: Evidence of continuing racial and ethnic differences. J Acquir Immune Defic Syndr. 2006 Dec 1;43(4): 451-7. (Pubitemid 44737104)
4. Chen RY, Accortt NA, Westfall AO, et al. Distribution of health care expenditures for HIV-infected patients. Clin Infect Dis. 2006 Apr 1;42(7):1003-10.
5. Lifson AR, Allen S, Wolf W, et al. Classification of HIV infection and disease in women from Rwanda: Evaluation of the World Health Organization HIV staging system and recommended modifications. Ann Intern Med. 1995 Feb 15;122(4):262-70.
6. Malamba SS, Morgan D, Clayton T, et al. The prognostic value of the World Health Organization staging system for HIV infection and disease in rural Uganda. AIDS. 1999 Dec 24;13(18):2555-62. (Pubitemid 30038034)
7. Tassie JM, Marquardt T, Damisoni H, et al. Indirect markers to initiate highly active antiretroviral therapy in a rural African setting. AIDS. 2004 May 21;18(8):1226-8. (Pubitemid 38738531)
8. World Health Organization (WHO). WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. Geneva, Switzerland: WHO Press, 2007. Available at: Http://www who.int/hiv/pub/guidelines/hivstaging/en/index. html. Accessed August 1, 2008.
9. Centers for Disease Control and Prevention (CDC). Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged ,18 months and for HIV infection and AIDS among children aged 18 months to ,13 years-United States, 2008. MMWR Morb Mortal Wkly Rep. 2008 Dec 5;57(No. RR-10):1-8.
10. Jaffar S, Birungi J, Grosskurth H, et al. Use of WHO clinical stage for assessing patient eligibility to antiretroviral therapy in a routine health service setting in Jinja, Uganda. AIDS Res Ther. 2008 Feb 28;5:4.
11. Kassa E, Rinke de Wit TF, Hailu E, et al. Evaluation of the World Health Organization's staging system for HIV infection and disease in Ethiopia: Association between clinical stages and laboratory markers. AIDS. 1999 Feb 25;13(3):381-9. (Pubitemid 29095101)
12. Teck R, Ascurra O, Gomani P, et al. WHO clinical staging of HIV infection and disease, tuberculosis and eligibility for antiretroviral treatment: Relationship to CD4 lymphocyte counts. Int J Tuberc Lung Dis. 2005 Mar;9(3):258-62. (Pubitemid 40392939)